Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.90B | 1.74B | 1.66B | 1.36B | 966.22M | 817.08M |
Gross Profit | 186.74M | 176.85M | 161.50M | 134.78M | 63.66M | 82.58M |
EBITDA | 30.14M | 24.25M | 27.18M | -14.55M | -214.97M | 27.22M |
Net Income | 14.84M | 14.38M | 23.08M | -12.06M | -190.65M | 31.24M |
Balance Sheet | ||||||
Total Assets | 1.27B | 1.14B | 999.90M | 792.81M | 686.37M | 328.97M |
Cash, Cash Equivalents and Short-Term Investments | 390.13M | 491.15M | 389.51M | 347.99M | 320.58M | 84.63M |
Total Debt | 6.64M | 5.59M | 8.29M | 11.50M | 46.50M | 33.66M |
Total Liabilities | 539.00M | 452.34M | 392.51M | 273.76M | 236.19M | 185.32M |
Stockholders Equity | 682.86M | 635.18M | 561.44M | 499.09M | 426.87M | 146.75M |
Cash Flow | ||||||
Free Cash Flow | 96.87M | 109.28M | 80.67M | 47.09M | 54.51M | 38.51M |
Operating Cash Flow | 91.86M | 109.28M | 80.78M | 47.20M | 55.06M | 38.89M |
Investing Cash Flow | -96.32M | -11.98M | -42.97M | -104.00K | -32.77M | -380.00K |
Financing Cash Flow | 7.24M | 4.33M | 3.71M | -19.68M | 213.66M | -767.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | 4.84B | 92.39 | 3.76% | ― | 20.60% | 0.00% | |
75 Outperform | $2.75B | 191.36 | 2.32% | ― | 12.05% | -2.46% | |
66 Neutral | 1.44B | 63.53 | 1.83% | ― | 6.39% | 0.00% | |
66 Neutral | 1.43B | -57.62 | -8.07% | ― | 15.31% | 77.02% | |
61 Neutral | 2.13B | 119.82 | 1.32% | 3.26% | -24.79% | -78.38% | |
51 Neutral | 984.72M | -5.22 | -18.04% | ― | -6.71% | -71.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On August 28, 2025, Privia Health Group announced its Accountable Care Organizations (ACOs) achieved $233.1 million in shared savings through the Medicare Shared Savings Program for 2024, marking a 32% increase from the previous year. This performance underscores the effectiveness of Privia’s physician-led approach and data-driven tools, benefiting nearly 195,000 Medicare beneficiaries. The company also increased its Adjusted EBITDA guidance for 2025 to $113-$116 million, reflecting its strong operational performance and strategic positioning in the healthcare industry.